RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Carolina Nunes(Ghent University), Frank Speleman(Ghent University)

Science Advances

July 13, 2022

10.1126/sciadv.abn1382

Cited by 47

Related Papers

Delineation of two distinct 6p deletion syndromes

|Human Genetics|1999|113

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma

|Cancer Letters|2015|50

MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells

|Scientific Reports|2021|8

Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

|Unknown|2023|0